Cue Biopharma, Inc. Overview
Pro stress-test →Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. The company focuses on treating cancer and autoimmune diseases through its proprietary Immuno-STAT platform, which aims to harness the body's intrinsic immune system without broad systemic immune modulation.
Strategic Profile
Pro stress-test →The company's lead programs include CUE-101 in phase 1b trials for HPV+ head and neck squamous cell carcinoma as both monotherapy and in combination with KEYTRUDA, and CUE-102 in phase 1b development for WT1+ colorectal, gastric, ovarian, and pancreatic cancers. Cue has collaboration agreements with LG Chem, Ono Pharmaceutical, and other partners to advance its pipeline.
Competitive Landscape
Pro stress-test →Cue competes in the immuno-oncology and cell therapy space against established players like Gilead (CAR-T), Juno Therapeutics, and emerging companies focused on T cell engineering. Its differentiation lies in the Immuno-STAT platform's selectivity in modulating disease-specific T cells without broad immunosuppression. The competitive landscape includes both large pharma collaborators (Boehringer Ingelheim, Ono) and smaller biotech rivals pursuing similar T cell approaches.
Industry Context
Cue Biopharma, Inc. operates in Biopharmaceutical - Immuno-Oncology / Cell Therapy.
Key facts
Headquarters: Boston, Massachusetts · Market cap: $25M